{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-25-000074","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.205542+00:00","generated_at":"2026-05-22T08:20:12.402578+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BeiGene reports Q1 2025 revenue $1.1B (+49% YoY); first GAAP profitable quarter with net income $1.3M","bullets":["Total revenue $1.1B (+49% YoY); BRUKINSA sales $792M (+62%), now overall BTKi leader.","First GAAP profitable quarter: net income $1.3M vs loss $251M in Q1 2024; adjusted net income $136M.","Adjusted diluted EPS $1.22 vs ($1.40) prior year; operating cash flow significantly improved.","Shareholder approved renaming to BeOne Medicines and redomicile to Switzerland; investor R&D Day June 26."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-25-000074","json":"https://secwatch.observer/filing/0001651308-25-000074.json","markdown":"https://secwatch.observer/filing/0001651308-25-000074.md","text":"https://secwatch.observer/filing/0001651308-25-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/0001651308-25-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/bgne-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:20:12.402578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}